Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related CREE
10 Stocks That Rallied Four Days, Then Sold Off On Friday
Cree's Post-Earnings Retreat Spurs Insider Buying
Related CI
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Economic Data

Analysts at Sterne Agee downgraded Cree (NASDAQ: CREE) from “buy” to “neutral.” The target price for Cree has been lowered from $66.00 to $59.00. Cree's shares closed at $61.11 yesterday.

Analysts at Jefferies downgraded Cigna (NYSE: CI) from “buy” to “hold.” The target price for Cigna has been lowered from $78.00 to $75.00. Cigna's shares closed at $69.03 yesterday.

Analysts at Stifel Nicolaus downgraded Crimson Exploration (NASDAQ: CXPO) from “buy” to “hold.” The target price for Crimson Exploration is set to $3.75. Crimson Exploration's shares closed at $3.14 yesterday.

Goldman Sachs downgraded AVG Technologies N.V. (NYSE: AVG) from “buy” to “neutral.” The target price for AVG Technologies has been raised from $18.00 to $18.50. AVG Technologies' shares closed at $17.48 yesterday.

Latest Ratings for CREE

DateFirmActionFromTo
Oct 2016Stephens & Co.DowngradesOverweightEqual-Weight
Sep 2016Williams CapitalInitiates Coverage onBuy
Sep 2016Canaccord GenuityAssumesHold

View More Analyst Ratings for CREE
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (CI + AVG)

View Comments and Join the Discussion!